Clozapine in tardive dyskinesia

Observations from human and animal model studies

C. A. Tamminga, G. K. Thaker, M. Moran, T. Kakigi, X. M. Gao

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.

Original languageEnglish (US)
Pages (from-to)102-106
Number of pages5
JournalJournal of Clinical Psychiatry
Volume55
Issue number9 SUPPL. B
StatePublished - 1994

Fingerprint

Clozapine
Animal Models
Haloperidol
Therapeutics
Mastication
Dyskinesias
Movement Disorders
Antipsychotic Agents
Tardive Dyskinesia
Schizophrenia
Hypersensitivity
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Tamminga, C. A., Thaker, G. K., Moran, M., Kakigi, T., & Gao, X. M. (1994). Clozapine in tardive dyskinesia: Observations from human and animal model studies. Journal of Clinical Psychiatry, 55(9 SUPPL. B), 102-106.

Clozapine in tardive dyskinesia : Observations from human and animal model studies. / Tamminga, C. A.; Thaker, G. K.; Moran, M.; Kakigi, T.; Gao, X. M.

In: Journal of Clinical Psychiatry, Vol. 55, No. 9 SUPPL. B, 1994, p. 102-106.

Research output: Contribution to journalArticle

Tamminga, CA, Thaker, GK, Moran, M, Kakigi, T & Gao, XM 1994, 'Clozapine in tardive dyskinesia: Observations from human and animal model studies', Journal of Clinical Psychiatry, vol. 55, no. 9 SUPPL. B, pp. 102-106.
Tamminga, C. A. ; Thaker, G. K. ; Moran, M. ; Kakigi, T. ; Gao, X. M. / Clozapine in tardive dyskinesia : Observations from human and animal model studies. In: Journal of Clinical Psychiatry. 1994 ; Vol. 55, No. 9 SUPPL. B. pp. 102-106.
@article{3ba7ad27f960498584f05261847adc4c,
title = "Clozapine in tardive dyskinesia: Observations from human and animal model studies",
abstract = "Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.",
author = "Tamminga, {C. A.} and Thaker, {G. K.} and M. Moran and T. Kakigi and Gao, {X. M.}",
year = "1994",
language = "English (US)",
volume = "55",
pages = "102--106",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "9 SUPPL. B",

}

TY - JOUR

T1 - Clozapine in tardive dyskinesia

T2 - Observations from human and animal model studies

AU - Tamminga, C. A.

AU - Thaker, G. K.

AU - Moran, M.

AU - Kakigi, T.

AU - Gao, X. M.

PY - 1994

Y1 - 1994

N2 - Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.

AB - Clozapine has long been considered a useful treatment in patients who have schizophrenia with the neuroleptic-induced delayed-onset side effect tardive dyskinesia. We present data in support of that clinical impression using both an animal model of the disorder and dyskinetic patients themselves. Clozapine produces a lower rate of oral dyskinesia in laboratory rats after 6 months of chronic treatment than does haloperidol (8.6 ± 1.3 vs. 13.6 ± 1.4 vacuous chewing movements every 5 minutes, respectively), suggesting a lower propensity to cause tardive dyskinesia. In the human, when clozapine was compared with haloperidol in the treatment of patients with tardive dyskinesia, clozapine produced significantly greater benefit for motor symptoms after 12 months of treatment than did haloperidol (p < .001). Moreover, the dyskinesia rebound, which occurred equally in both drug groups at the beginning of the study, was sustained in the haloperidol group but lost in the clozapine-treated patients. These data suggest that dyskinetic patients lose their symptoms of tardive dyskinesia, along with dopaminergic hypersensitivity, with long-term clozapine treatment.

UR - http://www.scopus.com/inward/record.url?scp=0027984221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027984221&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 102

EP - 106

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 9 SUPPL. B

ER -